BT-11 Active ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease

---

Clinical trials : 2,400 /  Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03860571 (ClinicalTrials.gov)	July 6, 2018	3/2/2019	Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers	A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers	Ulcerative Colitis;Crohn Disease	Drug: BT-11 Placebo;Drug: BT-11 Active	Landos Biopharma Inc.	NULL	Completed	18 Years	65 Years	All	70	Phase 1	United States

97. Ulcerative colitis

---

Clinical trials : 2,527 /  Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03860571 (ClinicalTrials.gov)	July 6, 2018	3/2/2019	Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers	A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers	Ulcerative Colitis;Crohn Disease	Drug: BT-11 Placebo;Drug: BT-11 Active	Landos Biopharma Inc.	NULL	Completed	18 Years	65 Years	All	70	Phase 1	United States